ArticleJOR spine2026
Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.
Article in JOR spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Background: Diabetes mellitus (DM) is a major risk factor for postoperative infection and wound complications in spine surgery, yet distinctions between Type 2 (T2DM) and Type 1 (T1DM) pathophysiology are rarely addressed. This study compares infectious burden, wound healing, and immune response among a murine model of spinal implant-associated infection of T2DM, T1DM, and nondiabetic control mice before and after metabolic intervention with the GLP-1 receptor agonist (GLP-1RA), semaglutide. Methods: Male C57BL/6J mice were rendered diabetic by streptozotocin induction (T1DM) or a high-fat, high-sucrose diet (T2DM). Spinal implants were placed and inoculated with bioluminescent Results: Both diabetic models demonstrated greater infection burden, delayed wound healing, and distinct systemic inflammatory profiles compared with controls. T2DM was characterized by chronically elevated baseline inflammation and a blunted acute response to infection, whereas T1DM exhibited low baseline activity but exaggerated and dysregulated cytokine induction. Semaglutide attenuated infection severity, improved wound integrity, and partially normalized inflammatory patterns. Histology and immunofluorescence corroborated these findings, showing reduced immune cell infiltration and improved tissue organization in semaglutide-treated cohorts. Conclusions: T2DM and T1DM are associated with differing inflammatory and immune features in murine spinal implant-associated infection. Metabolic modulation with semaglutide restores immune balance, reduces infection severity, and promotes wound repair. These findings support exploration of GLP-1RA-based therapies to improve surgical outcomes in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.